Using a blood test to guide extra treatment after stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new way to guide treatment after surgery for stomach cancer. It uses a blood test to look for tiny pieces of cancer DNA, and then gives extra treatment only to people who still have signs of cancer. The goal is to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with stomach cancer or cancer where the stomach meets the food pipe, and you haven't had treatment yet.
- Your cancer is at a stage where it can be removed by surgery (stage III or IVA), and it hasn't spread to distant organs.
- Your cancer is HER2-negative, meaning it doesn't have a certain protein that some treatments target.
- You are between 18 and 75 years old and are healthy enough for surgery.
- Your heart, liver, kidneys, and blood counts are within normal ranges, and you don't have active infections like hepatitis B or C.
- You are willing to have a blood test to look for cancer DNA (ctDNA) and possibly get extra treatment based on those results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
This study looks at using a blood test that finds tiny bits of cancer DNA to decide if you need extra chemotherapy after surgery. It aims to make treatment more personalized and reduce side effects for people with locally advanced stomach cancer.
This trial is testing whether using a blood test to find tiny amounts of cancer DNA after initial treatment can guide decisions about further therapy for people with stomach cancer. The goal is to personalize follow-up treatment to reduce the chance of cancer returning.
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
Hear when a new ctDNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.